Comparative Pharmacology
Head-to-head clinical analysis: FLUXID versus PRILOSEC OTC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLUXID versus PRILOSEC OTC.
FLUXID vs PRILOSEC OTC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
FLUXID is a selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity by blocking the reuptake of serotonin at the presynaptic neuronal membrane, increasing serotonin availability in the synaptic cleft.
Proton pump inhibitor that irreversibly inhibits the H+/K+ ATPase enzyme (proton pump) in gastric parietal cells, suppressing gastric acid secretion.
1-2 g IV every 8 hours; maximum 6 g/day.
20 mg orally once daily for 14 days for frequent heartburn; may repeat 14-day course every 4 months.
None Documented
None Documented
Terminal half-life: 12 hours (range 10–14 hours). In renal impairment (CrCl <30 mL/min), half-life prolonged to 24–36 hours; dose adjustment required.
Approximately 0.5–1 hour in healthy subjects; longer (up to 3 hours) in slow metabolizers or hepatic impairment. Clinically, the duration of acid suppression exceeds the half-life due to accumulation in parietal cell canaliculi.
Renal: 70% unchanged; Fecal: 20%; Biliary: 10%.
Primarily hepatic metabolism; about 80% of metabolites are excreted in urine, and the remainder in feces via bile. Less than 1% of unchanged drug is excreted in urine.
Category C
Category C
Proton Pump Inhibitor
Proton Pump Inhibitor